RESUMO
Epidermal growth factor receptor inhibitors are anti-tumour agents that are frequently used for the treatment of neoplastic disorders. In addition to their cutaneous adverse effects, these drugs can rarely lead to erosive pustular dermatosis of the scalp. We report a case of a 67-year-old female who developed erosive pustular dermatosis of the scalp after being started on erlotinib from a trichoscopic perspective, which has been described in literature only once till now.
Assuntos
Antineoplásicos , Dermatoses do Couro Cabeludo , Feminino , Humanos , Idoso , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatoses do Couro Cabeludo/patologia , Cloridrato de Erlotinib/efeitos adversos , Couro Cabeludo/patologia , Antineoplásicos/uso terapêuticoAssuntos
Exantema , Dermatoses do Couro Cabeludo , Dermatopatias Vesiculobolhosas , Humanos , Panitumumabe/efeitos adversos , Couro Cabeludo , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatopatias Vesiculobolhosas/induzido quimicamente , Dermatopatias Vesiculobolhosas/tratamento farmacológicoRESUMO
Gefitinib is a selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) used for the treatment of malignant neoplasms. The most frequent skin complication during gefitinib therapy is an acneiform papulopustular eruption, usually distributed in the seborrheic areas but occasionally widespread. We report a patient with erosive pustular dermatosis of the scalp, a neutrophil-mediated skin disease presenting with sterile pustules evolving into erosions and crusts on the scalp, during treatment with the EGFR inhibitor gefitinib for lung cancer. A literature review of the drug-induced cases of this rare entity is provided.
Assuntos
Antineoplásicos/efeitos adversos , Toxidermias/etiologia , Gefitinibe/efeitos adversos , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatopatias Vesiculobolhosas/induzido quimicamente , Idoso de 80 Anos ou mais , Humanos , MasculinoAssuntos
Compostos Azo/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Tinturas para Cabelo/efeitos adversos , Testes do Emplastro , Fenilenodiaminas/efeitos adversos , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatite Alérgica de Contato/diagnóstico , Interações Medicamentosas , Feminino , Humanos , Dermatoses do Couro Cabeludo/diagnóstico , Fatores de Tempo , Adulto JovemAssuntos
Dermatoses do Couro Cabeludo , Dermatopatias Vesiculobolhosas , Humanos , Nivolumabe/efeitos adversos , Couro Cabeludo , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatopatias Vesiculobolhosas/induzido quimicamente , Dermatopatias Vesiculobolhosas/diagnósticoAssuntos
Benzoquinonas/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Óleos de Plantas/efeitos adversos , Alérgenos/efeitos adversos , Alopecia/tratamento farmacológico , Benzoquinonas/imunologia , Reações Cruzadas/imunologia , Dermatite Alérgica de Contato/imunologia , Dermatoses Faciais/induzido quimicamente , Feminino , Humanos , Hidroquinonas/imunologia , Pessoa de Meia-Idade , Nigella sativa , Dermatoses do Couro Cabeludo/induzido quimicamenteAssuntos
Antitireóideos/efeitos adversos , Carbimazol/efeitos adversos , Displasia Ectodérmica/induzido quimicamente , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatoses do Couro Cabeludo/congênito , Adulto , Feminino , Humanos , Recém-Nascido , Gravidez , Complicações na Gravidez/tratamento farmacológicoAssuntos
Anticonvulsivantes/efeitos adversos , Toxidermias/etiologia , Lamotrigina/efeitos adversos , Pseudolinfoma/induzido quimicamente , Anticonvulsivantes/administração & dosagem , Criança , Toxidermias/diagnóstico , Toxidermias/patologia , Feminino , Humanos , Lamotrigina/administração & dosagem , Pseudolinfoma/diagnóstico , Dermatoses do Couro Cabeludo/induzido quimicamente , Dermatoses do Couro Cabeludo/diagnóstico , Dermatoses do Couro Cabeludo/patologiaRESUMO
BACKGROUND: An essential step in ensuring the toxicological safety of cosmetic or personal care products is the evaluation of the skin sensitizing potential of product ingredients. OBJECTIVE: We used a standardized protocol from cosmetic trade industry and consumer safety groups to evaluate the sensitization potential of ingredients in 3 commercially available cleansing conditioners. METHODS: A total of 33 ingredients were evaluated. Each ingredient underwent (1) dermatological evaluation, (2) in silico analysis for irritation and sensitization potential, and (3) a literature evaluation to determine risk of sensitization. Consumer exposure level was compared with the weight-of-evidence no-expected sensitization induction level for the constituent. If a no-expected sensitization induction level for a specific ingredient was not available, the dermal sensitization threshold approach was used. A margin of safety was calculated for each constituent. RESULTS: The margins of safety for all evaluated ingredients in the cleansing conditioners were greater than 1. CONCLUSIONS: This analysis indicates that exposure to the individual ingredients present in these cleansing conditioners would not be expected to induce dermal sensitization in a consumer under the examined exposure scenario.